This article summarises available evidence, highlights gaps and proposes practical approaches for safe, effective switching
You do however have pernicious anemia & all of your symptoms are caused by that
(Exenatide is FDA approved as monotherapy for the management of T2DM.) Explicitly stated in the guideline for patients requiring dual or triple therapy, the AACE/ACE preferentially recommends the addition of a GLP-1 receptor agonist or a DPP-4 inhibitor (sitagliptin, saxagliptin), citing their efficacy and safety profiles as preferred agents over TZDs or sulfonylureas (SUs)
With law offices in Miami, New York City, and the San Francisco Bay Area, our firm has represented more than 160 million people in legal actionsthats roughly 1 in every 2 Americans
See Description section for vitamin strengths [see Description (11)]
10.1186/s12967-015-0417-0 182 ZhangY.LinX.DaiY.HuX.ZhuH.JiangY.et al (2016)